Polycomb-independent activity of EZH2 in castration resistant prostate cancer

被引：0
|
作者：
Kexin Xu
Zhenhua Jeremy Wu
Anna C Groner
Housheng Hansen He
Changmeng Cai
Edward C Stack
Massimo Loda
Tao Liu
Colm Morrissey
Robert L Vessella
Philip W Kantoff
Steven P Balk
X Shirley Liu
Myles Brown
机构：
[1] Dana-Farber Cancer Institute,Center for Functional Cancer Epigenetics
[2] Dana-Farber Cancer Institute and Harvard Medical School,Department of Medical Oncology
[3] Dana-Farber Cancer Institute and Harvard School of Public Health,Department of Biostatistics and Computational Biology
[4] Beth Israel Deaconess Medical Center and Harvard Medical School,Hematology
[5] Dana-Farber Cancer Institute,Oncology Division, Department of Medicine
[6] Harvard Medical School,Center for Molecular Oncologic Pathology
[7] King’s College London,Department of Pathology, Brigham and Women’s Hospital
[8] University of Washington Medical Center,Division of Cancer Studies
[9] Puget Sound VA Health Care System,Department of Urology
来源：
Epigenetics & Chromatin | / 6卷 / Suppl 1期
关键词：
Androgen Receptor; Acute Leukemia; Castration Resistant Prostate Cancer; Histone Methyltransferase; Methyltransferase Activity;
D O I：
10.1186/1756-8935-6-S1-O14
中图分类号：
学科分类号：
摘要：
引用
收藏
相关论文
共 50 条
  • [31] A PRC2 independent role of EZH2 in androgen receptor signaling in prostate cancer
    Lee, Yongik
    Kim, Jung A.
    Zhao Changsheng
    Lu, Xiadong
    Fong, Ka Wing
    Yu, Jindan
    CANCER RESEARCH, 2018, 78 (13)
  • [32] Lycopene enhances the sensitivity of castration-resistant prostate cancer to enzalutamide through the AKT/EZH2/androgen receptor signaling pathway
    Chen, Xiong
    Yang, Guo
    Liu, Miao
    Quan, Zhen
    Wang, Leilei
    Luo, Chunli
    Wu, Xiaohou
    Zheng, Yongbo
    BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, 2022, 613 : 53 - 60
  • [33] Combined therapy targeting AR and EZH2 restrains the growth of castration resistant prostate cancer by enhancing antitumor T cell response
    Fischetti, Irene
    Laura, Botti
    Sulsenti, Roberta
    Cancila, Valeria
    Enriquez, Claudia
    Ferri, Renata
    Bregni, Marco
    Crivelli, Filippo
    Tripodo, Claudio
    Colombo, Mario P.
    Jachetti, Elena
    CANCER RESEARCH, 2024, 84 (06)
  • [34] The Role of EZH2 in the Regulation of the Activity of Matrix Metalloproteinases in Prostate Cancer Cells
    Shin, Yong Jae
    Kim, Jeong-Ho
    PLOS ONE, 2012, 7 (01):
  • [35] The role of EZH2 in the regulation of the activity of matrix metalloproteinases in prostate cancer cells
    Shin, Yong Jae
    Kim, Jeong-Ho
    CANCER RESEARCH, 2012, 72
  • [36] Functional role of EZH2 in neuroendocrine prostate cancer
    Khalil, Md Imtiaz
    Yang, Shu
    Blankenship, Anthony
    Connelly, Zachary
    Yu, Xiuping
    CANCER RESEARCH, 2019, 79 (13)
  • [37] Repression of E-cadherin by the polycomb group protein EZH2 in cancer
    Q Cao
    J Yu
    S M Dhanasekaran
    J H Kim
    R-S Mani
    S A Tomlins
    R Mehra
    B Laxman
    X Cao
    J Yu
    C G Kleer
    S Varambally
    A M Chinnaiyan
    Oncogene, 2008, 27 : 7274 - 7284
  • [38] Genetic Polymorphisms in the Polycomb Group Gene EZH2 and the Risk of Lung Cancer
    Yoon, Kyong-Ah
    Gil, Hye Jin
    Han, Jihye
    Park, Jaehee
    Lee, Jin Soo
    JOURNAL OF THORACIC ONCOLOGY, 2010, 5 (01) : 10 - 16
  • [39] The polycomb group protein EZH2 is a novel therapeutic target in tongue cancer
    Li, Zhongwu
    Wang, Yanling
    Qiu, Jing
    Li, Qiang
    Yuan, Chunping
    Zhang, Wei
    Wang, Dongmiao
    Ye, Jinhai
    Jiang, Hongbin
    Yang, Jianrong
    Cheng, Jie
    ONCOTARGET, 2013, 4 (12) : 2532 - 2549
  • [40] Repression of E-cadherin by the polycomb group protein EZH2 in cancer
    Cao, Q.
    Yu, J.
    Dhanasekaran, S. M.
    Kim, J. H.
    Mani, R-S
    Tomlins, S. A.
    Mehra, R.
    Laxman, B.
    Cao, X.
    Yu, J.
    Kleer, C. G.
    Varambally, S.
    Chinnaiyan, A. M.
    ONCOGENE, 2008, 27 (58) : 7274 - 7284
12345